[HTML][HTML] Clinical utility of liquid biopsy-based companion diagnostics in the non-small-cell lung cancer treatment
Y Sato - Exploration of Targeted Anti-Tumor Therapy, 2022 - ncbi.nlm.nih.gov
Recently, technological advances in the detection and biological characterization of
circulating tumor DNA (ctDNA) have enabled the implementation of liquid biopsy testing into …
circulating tumor DNA (ctDNA) have enabled the implementation of liquid biopsy testing into …
Role of circulating-tumor DNA in the early-stage non-small cell lung carcinoma as a predictive biomarker
SR Khan, M Scheffler, SM Soomar, YA Rashid… - … -Research and Practice, 2023 - Elsevier
Lung cancer is one of the most common solid malignancies. Tissue biopsy is the standard
method for accurately diagnosing lung and many other malignancies over decades …
method for accurately diagnosing lung and many other malignancies over decades …
[HTML][HTML] The reproducibility of MTV and TLG of soft tissue tumors calculated by FDG-PET: Comparison between the lower limit by the fixed value SUV 2.5 and that …
H Iwasa, S Nagamachi, S Nakayama… - Japanese Journal of …, 2023 - Springer
Purpose We evaluated the reproducibility calculating volume-based FDG-PET/CT
parameters, ie, metabolic tumor volume (MTV) and total lesion glycolysis (TLG), in soft tissue …
parameters, ie, metabolic tumor volume (MTV) and total lesion glycolysis (TLG), in soft tissue …
[HTML][HTML] Imaging and Liquid Biopsy for Distinguishing True Progression From Pseudoprogression in Gliomas, Current Advances and Challenges
K Li, Q Zhu, J Yang, Y Zheng, S Du, M Song, Q Peng… - Academic …, 2024 - Elsevier
Rationale and Objectives Gliomas are aggressive brain tumors with a poor prognosis.
Assessing treatment response is challenging because magnetic resonance imaging (MRI) …
Assessing treatment response is challenging because magnetic resonance imaging (MRI) …
[HTML][HTML] Associations between detectable circulating tumor DNA and tumor glucose uptake measured by 18F-FDG PET/CT in early-stage non-small cell lung cancer
AL Ottestad, H Johansen, TO Halvorsen, HY Dai… - BMC cancer, 2023 - Springer
Background The low level of circulating tumor DNA (ctDNA) in the blood is a well-known
challenge for the application of liquid biopsies in early-stage non-small cell lung cancer …
challenge for the application of liquid biopsies in early-stage non-small cell lung cancer …
[HTML][HTML] Circulating Tumor DNA correlates with Lactate Dehydrogenase, CYFRA 21-1, and CRP levels in patients with advanced NSCLC
M Buresova, L Benesova, M Minarik, R Ptackova… - Journal of …, 2023 - ncbi.nlm.nih.gov
Purpose: To investigate potential association between selected tumor markers and
laboratory parameters (lactate dehydrogenase [LDH], neutrophils, hemoglobin, neutrophils …
laboratory parameters (lactate dehydrogenase [LDH], neutrophils, hemoglobin, neutrophils …
[HTML][HTML] Clinical value of peripheral blood circulating tumor DNA in predicting the efficacy of immunotherapy for non-small cell lung cancer
J Wang, X Fan, J Zhang, C Huang - Journal of Thoracic Disease, 2023 - ncbi.nlm.nih.gov
Background The high expression of programmed cell death 1-ligand 1 (PD-L1) is a valid
biological indicator of the therapeutic benefit of pembrolizumab in non-small cell lung cancer …
biological indicator of the therapeutic benefit of pembrolizumab in non-small cell lung cancer …